Connor, Clark & Lunn Investment Management Ltd. Albireo Pharma, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $22 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023
SELL
$18.01 - $23.78 $6,069 - $8,013
-337 Reduced 3.35%
9,724 $210,000
Q3 2022

Nov 10, 2022
BUY
$16.32 - $26.37 $164,195 - $265,308
10,061 New
10,061 $195,000
Q2 2022

Aug 05, 2022
SELL
$18.54 - $37.29 $337,372 - $678,566
-18,197 Closed
0 $0
Q1 2022

May 12, 2022
BUY
$23.94 - $33.74 $34,473 - $48,585
1,440 Added 8.59%
18,197 $543,000
Q4 2021

Feb 10, 2022
BUY
$21.19 - $31.29 $355,080 - $524,326
16,757 New
16,757 $390,000

Others Institutions Holding ALBO

# of Institutions
4
Shares Held
865
Call Options Held
0
Put Options Held
0
View Full List

About ALBIREO PHARMA, INC.

ALBO Quotes by TradingView
  • Ticker ALBO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 19,612,500
  • Description
  • Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...
More about ALBO
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email